"The U.S. Food and Drug Administration today approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections.
Orbactiv is approved to treat patients with acute bacterial skin and skin structure infections (ABSS"...
- Patients using this medication should receive the following informa-tion and instructions:
- The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.
- Even if symptomatic relief occurs within the first few days of treat-ment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.
If symptoms of irritation develop, the patient should be advised to notify the physician promptly.
Last reviewed on RxList: 11/26/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Nystop Information
Nystop - User Reviews
Nystop User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.